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Objective: To identify bronchoscopy-related complications and discomfort, meaningful complication rates,
and predictors.
Method: We conducted a systematic literature search in PubMed on 8 February 2016, using a search strategy
including the PICO model, on complications and discomfort related to bronchoscopy and related sampling
techniques.
Results: The search yielded 1,707 hits, of which 45 publications were eligible for full review. Rates of mortality
and severe complications were low. Other complications, for instance, hypoxaemia, bleeding, pneumothorax,
and fever, were usually not related to patient characteristics or aspects of the procedure, and complication
rates showed considerable ranges. Measures of patient discomfort differed considerably, and results were
difficult to compare between different study populations.
Conclusion: More research on safety aspects of bronchoscopy is needed to conclude on complication rates and
patient- and procedure-related predictors of complications and discomfort.
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F
lexible bronchoscopy (FB) was introduced in 1968,
and today it is an essential procedure in respiratory
medicine. There are numerous indications for bron-
choscopy, and it is frequently used for diagnostic and
therapeutic purposes in both inpatients and outpatients.
White light FB is commonly used in diagnostics, as it
enables visualisation of the lower airways and sampling
techniques such as bronchial brushings (BB), bronchial
washings (BW), bronchoalveolar lavage (BAL), endobron-
chial biopsies (EBB), transbronchial biopsies (TBB), and
transbronchial needle aspiration (TBNA) (1).
Bronchoscopy is generally considered safe (2). How-
ever, whether performed with anaesthesia or only light
sedation, pre-procedural medications are routinely admi-
nistered and may have side effects. Diagnostic sampling
may lead to immediate, although rare, complications,
such as intrabronchial bleeding, bronchospasm, and
pneumothorax. In addition, some discomfort may be
felt in the days after the procedure, such as fever, sore
throat, cough, or reactions to the medications used (1).
Events occurring after the observation period may not be
detected by the bronchoscopist. To ensure that both the
bronchoscopy team and the patient are adequately pre-
pared for the procedure, a realistic picture of the potential
for complications and discomfort is imperative.
To the best of our knowledge, there is no recent sys-
tematic review of complications and discomfort associa-
ted with bronchoscopy. The 2013 British Thoracic Society
Guidelines (2) includes a comprehensive overview of
complications, but only presents a few selected references
without discussing potential weaknesses of the included
studies.
Thus, we set out to conduct a systematic review of
complications and patient discomfort associated with non-
interventional bronchoscopy, and the frequency and
predictors of these in patients and research subjects.
Methods
We used a modified Population - Intervention - Outcome
comparison (PICO) form (3) (Table 1) and performed
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a systematic literature search in PubMed (Medline). Key-
words were selected by combining existing thesauruses
(MeSH terms) and text words. We performed a review of
the existing MeSH database and of the (MeSH) classifica-
tion of relevant papers that were already published. In
addition, we added text words considered relevant to
describe complications known to the authors.
The search in PubMed was conducted on 8 February
2016.
We included publications in English, Norwegian, Swed-
ish, Danish, and French. Case reports, non-original
research (letters, review articles, guidelines, etc.), animal
studies, studies solely based on interventional procedures
and specialised examination techniques, studies on pae-
diatric populations as well as studies of intubated patients,
patients on mechanical ventilation, under general anaes-
thesia or in an intensive care unit (ICU), were excluded,
along with publications that did not cover the topic on
complications or discomfort associated with bronchoscopy.
Studies on bronchoscopes as a source of contamination
were considered outside the scope of the current review.
Papers were classified as prospective or retrospective,
and whether investigation of complications and discom-
fort was considered an objective (primary, secondary, not
formalised). We also divided articles into three groups
based on the number of subjects in the study and identi-
fied studies on medication during or before bronchoscopy.
Full review was only performed on papers where
complications or discomfort was a primary or secondary
objective of the study, where the number of subjects
exceeded 50, and where there was given a sufficient
description of the sample and the sampling methods
(inclusion/exclusion criteria, definition of endpoints, and
data collection). We chose to exclude papers based on less
than 50 subjects since the statistical power of these
studies in detecting rare complications is bound to be low.
Results
The initial literature search yielded 1,707 papers, of
which 1,435 were excluded (Table 2). In total, 94 papers
reported complications and discomfort as their primary or
Table 1. Search word combinations, in a modified PICO
form for a systematic literature search on complications and
discomfort related to bronchoscopy
We are interested in
a procedure called
(Intervention 1)
Where . . . is
performed.
(Intervention 2)
Will it lead to . . .?
(Outcome)
Bronchoscopy Bronchoalveolar
lavage
Complicationa
BAL Discomfort
Brusha Cougha
Transbronchial biopsy Saturation decrease
Endobronchial biopsy Adverse events
Bronchial biopsy Adverse effects
Conscious sedation Bronchospasm
Lidocaine Death
Pneumothorax
Shortness of breath
Dyspnoea
Bleeding
Haemorrhage
Fever
Vasovagal syncope
Cardiac arrest
Contraindication
Safety
Patient experience
Adverse symptoms
Anxiety
Pain
Hospitalisation
aTruncation. The content of columns was combined with OR.
Different columns were combined with AND.
Table 2. Yield of a PubMed  literature search on discomfort
and complications related to bronchoscopy (8 February 2016)
Number of
articles
Total in search 1,707
Type of publications
Excluded, non-original 214
Excluded, language 183
Excluded, case studies 268
Excluded, not human 37
Type of bronchoscopy
Excluded, provocation test 24
Excluded, interventional bronchoscopy 26
Excluded, general anaesthesia/intubated/
mechanical ventilation/ICU
149
Excluded, endobronchial ultrasound (EBUS) 32
Excluded, experimental or non-standard
bronchoscopy techniques
7
General
Excluded, no relevance/does not address
complications nor patient experience
381
Excluded, children 110
Excluded, disease outbreak study 3
Excluded, did not report according to
objectivea
1
Publications excluded, total 1,435
Publications remaining, total 272
aOne study did not report complications, despite the objective
‘(. . .) to document any complications’.
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secondary objective in procedures on more than 50 subjects
(Table 3). Of these papers, 15 did not define outcomes
sufficiently (418), five papers did not give information
on the data collection (6, 7, 13, 14, 19), four papers were
based on surveys of health care suppliers (2023), and
inclusion or exclusion criteria were not specified in 37
papers (8, 9, 12, 17, 2052). Thus, further review was
performed on the remaining 45 publications. The articles
are subsequently reviewed with respect to the subtopics:
death, bleeding, pneumothorax, bronchospasm, hypoxae-
mia, haemodynamic variations, fever and infection, health
care utilisation, coughing, other respiratory symptoms and
signs, and identified discomfort and pain The publications
are further described in the Supplementary file.
Death
Nine papers specified death as a potential outcome
(5361). The studies comprised 71702 subjects (53,
61). All studies, except Grendelmeier et al. (59, 61),
were conducted on selected populations (mostly immu-
nocompromised individuals). As in all but one study (53),
Grendelmeier et al. report a mortality rate of 0% (59, 61).
Bleeding
Bleeding rates varied between 2.5 and 89.9% in the
prospective studies and drug studies (59, 62). The studies
comprised 881,217 subjects (63, 64). Some studies graded
severity of bleeding according to volume (58, 62, 6567),
whereas others graded in terms of required intervention
(63, 64, 6870). Three studies did not define bleeding (59,
61, 71). Carr et al. aimed to investigate actual blood loss in
234 patients with low risk of bleeding. They categorised
bleeding as minimal (B5 ml), mild (520 ml), moderate
(20100 ml), and severe (100 ml) and found that 89.7%
had minimal bleeding, 8.1% had mild bleeding, and 2.1%
had moderate bleeding. No patients had severe bleeding.
Superior vena cava syndrome and addition of EBB and
TBB to TBNA predicted bleeding (62).
Pneumothorax
Six prospective studies (57, 58, 6466, 72) and two retros-
pective studies (55, 73) listed pneumothorax as a poten-
tial outcome, with rates ranging from 0 to 4% (58, 72).
Two studies reported no pneumothoraces in various
bioptic techniques that included TBB (66, 72). Jain et al.
reported 4% pneumothorax but did not relate complica-
tions to the specific procedure (58). Dang et al. reported
that pneumothorax occurred in three patients at a rate
of 1.6% when expressed as a percentage of TBB. One
pneumothorax required intervention (57). Herth et al.
conducted a study on 1,217 patients going through TBB
and found that 26 of them (2.1%) developed pneu-
mothoraces, of which 14 were treated with tube thora-
costomy, and the remaining 12 required no intervention
(64). There were no prospective studies reporting pneu-
mothorax as a result of other sampling procedures, such
as brush sampling or lavage.
A large, retrospective population-based register study
found that 0.97% (95% confidence interval (CI): 0.941.01%)
of transbronchial lung biopsies were complicated by a
pneumothorax that required chest tube placement (73).
Bronchospasm
Three prospective studies (57, 74, 75) and one retro-
spective study with prospective recordings of bronchos-
pasm (55) reported on bronchospasm. Bronchospasm
occurred at a rate between 0 and 12.3% (57, 75). The rate
of 12.3% was found in a study including asthma patients
exclusively (75).
Hypoxaemia
Ten studies provided information on hypoxaemia in un-
selected, elective patients (59, 61, 63, 7682). The studies
Table 3. Quantitative overview of articles from a systematic literature search on complications and discomfort of bronchoscopy,
divided into groups based on study design characteristics, number of subjects investigated, and relevance to the topic of
complications and discomfort
Subjects Primary objective Secondary objective Reports complication Claims ‘no complications’ Total
Prospective studies n200 14a 3a 4 0 21
n 50200 31a 2a 26 4 63
nB50 28 4 31 11 74
Retrospective studies n200 15a 4a 12 3 34
n 50200 3a 2a 13 2 20
nB50 8 7 7 7 29
Medication studies n200 5a 0 0 0 5
n 50200 15a 0 0 0 15
nB50 8 0 3 0 11
Total 127 22 96 27 272
aIn total, 94 articles reported complications and discomfort as their primary or secondary objective in procedures on more than
50 subjects.
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comprised 73702 subjects (61, 79). The majority of these
prospective studies and drug studies defined hypoxaemia,
or desaturation, as an oxygen saturation 590% (59, 61, 63,
7680, 82) or as a drop in pO2 to B60 mmHg at varying
time points (81). The papers reported desaturation rates
between 0.7 and 76.3% (80, 81). Rates around 75.0%
(duration not defined) were observed in both subjects
with (78) and without supplemental oxygen (77, 81).
Fruchter et al. aimed at conscious sedation (propofol),
which is defined as being able to rouse the patient by mild
prodding or shaking (78). Grendelmeier et al. reported
more mid-range results, with desaturation less than 90%
in 16.4% of 440 patients going through bronchoscopy
with propofol sedation, with conscious sedation defined
as onset ptosis (59). Of note is that only two out of
10 studies specified a level of hypoxaemia at which they
considered bronchoscopy contra-indicated (77, 79).
Haemodynamic variations
Eight drug studies (61, 70, 74, 76, 78, 79, 82, 83) and two
prospective studies (59, 63) reported haemodynamic
complications. The studies comprised 72702 subjects
(61, 79). In six papers, hypotension was regarded as a
systolic blood pressure (SBP) of B90 mmHg (59, 61, 63,
76, 78, 79) that required intervention (83). Hypotension
ranged from 2.9%, in patients sedated with propofol and
dexmedetomidine (79), to 28.9% in propofol sedation (61).
Two papers reported that 116% of participants needed
fluid resuscitation due to hypotension (78, 83). No paper
reported clinical outcome associated with hypotension.
Only two studies defined hypertension: one as SBP
180 mmHg or diastolic BP90 mmHg (63) and the other
as BP140/90 (79). Bradycardia was defined in three
studies, B60/min (79), B55/min (70), and B50/min, and
required intervention (83). All reported the incidence of
bradycardia to be 0. Two drug studies defined tachycardia,
100/min (79) and 130/min (70), and reported inci-
dence rates of 25.7% (79) and 8.0% (70), respectively. Ryu
reported 10.0% arrhythmias (79). Information regarding
the need of anti-arrhythmic therapy was not given in any of
these studies (70, 79).
Fever and infection
Elevation of body temperature was reported in seven
prospective studies (57, 65, 77, 8487) and one retro-
spective study with prospective recordings of temperature
(55). The studies comprised 50539 subjects (57, 85). The
range in incidence was 233% (77, 84). No studies used
comparable definitions of ‘fever’ or ‘temperature change’.
Krause et al. defined fever as a rise in body temperature
to 388C. Axillary body temperature was measured in
the morning prior to bronchoscopy and 3, 6, 12, and 24 h
after examination. In 20 patients, BAL was performed;
30 patients were examined by bronchoscopy only; 12
patients (24%) developed fever. There was no difference
between the BAL and non-BAL groups (85). González
Aguirre et al. reported an increased symptomatology in
65.1% post-FB and stated that this was mainly due to
fever. The number of patients experiencing fever was not
reported (87). Other signs, symptoms, and findings rela-
ted to infection were reported in six prospective studies
(75, 77, 8588). Yigla et al. studied 200 patients without
pre-procedural pulmonary infection and found a 6.5% of
bacteraemia rate following bronchoscopy (88). In a study
of asthma patients, 7% experienced respiratory infection
during the 2 weeks following bronchoscopy, but anti-
biotic treatment or other required intervention was not
reported (75). Krause et al. found flu-like symptoms in
8 out of 12 patients with fever, and two with chills and
severe constitutional symptoms, all of whom responded
well to Non Steroid Antiinflammatory Drugs (NSAIDs)
and subsided within 24 h (85). Pereira et al. reported that
one patient with protracted fever had a progressive
pneumonitis with a fatal outcome following broncho-
scopy despite antimicrobial drug therapy. All other cases
of fever subsided without antimicrobial treatment (86).
Health care utilisation
Nine prospective studies (5759, 61, 65, 68, 70, 84, 86)
reported complications that had to be handled by
increased health care utilisation. Similarly, five retro-
spective studies (5356, 73) reported events of increased
healthcare utilisation. Tukey and Wiener used health care
registers to identify pneumothoraces and haemorrhages
coded as iatrogenic and subsequently attributed them to
bronchoscopic procedures (73). The remaining studies
comprised 71702 subjects (53, 61). The incidence of
health care contacts ranged from 0 to 31%, (59, 60) but
was difficult to compare across different studies and
designs. We were not able to conclude regarding admis-
sion rates, prolonged observation after bronchoscopy, or
regarding assistance from outpatient/emergency room
services after the initial in-hospital observation.
Coughing
In some papers, coughing was referred to as a complica-
tion or adverse event (57, 59, 63, 65, 71, 75, 87, 89), and
in others it was simply a measure of discomfort (61, 72,
74, 82, 90, 91). Six prospective studies, comprising
57539 subjects (57, 75), reported cough by giving the
proportion of patients who experienced or were bothered
by coughing (57, 63, 65, 71, 72, 75). In these studies, the
rate ranged from 4.7 to 86.0% (65, 72). Procedural cough
was investigated in five articles (63, 65, 71, 72, 75). Post-
procedural cough was investigated in two papers, with an
incidence of 10.8% (57) and 55.7% (63). None of the
above-mentioned papers reported on the duration of
cough. Visual analogue scale (VAS), numeric rating scale
(NRS), and cough counting were the main rating tools of
cough in the drug trials; however, results were difficult to
compare as they investigated different drug regimens and
Elise Orvedal Leiten et al.
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primarily reported differences in cough related to seda-
tion or topical anaesthesia in subgroups within the trial.
Other respiratory symptoms and signs
Papers reporting on respiratory symptoms besides cough
and bronchospasm included five prospective studies (57,
61, 71, 75, 92). Two papers investigated change in asthma
symptom scores in a 2-week period following broncho-
scopy. Humbert et al. found no change in asthma score
(92), whereas Tapanainen et al. found that 5.3% had an
increase in asthma symptoms (75). Two papers reported
rates of dyspnoea between 3.5% (75) and 5.7% (57) as
observed by the researchers. In a study by Choi et al.,
self-reported shortness of breath was 38.2 and 30.9% in
subgroups of nasal and oral insertion of bronchoscope,
respectively (71). In other studies investigating patient-
reported dyspnoea, rates were not possible to extract as
only the ratios between subgroups were given in the
papers (5359, 61, 65, 68, 70, 73, 84, 86).
Identified discomfort and pain
Eight prospective studies (63, 71, 72, 77, 87, 89, 93, 94) and
12 drug studies (60, 61, 74, 76, 79, 82, 83, 90, 91, 9597)
reported subjective measures of patient satisfaction or
discomfort related to bronchoscopy. Numeric rating scales
(NRS), verbal analogue scales (VAS) and visual analogue
scales (VAS) were the most common assesment tools.
Several different scales were employed: verbal analogue
scales from 0 to 10 (63, 76): 10-point Likert scale (110)
(83); VAS 010 cm (with opposite orientations) (60, 82, 87,
90, 91, 96, 97); VAS 0100 mm (with opposite orientation)
(72, 89, 95); NRS 0100 (79); faces pain rating scale (05)
(74); and grading distress as no, some, or extreme distress
(77). Drug studies and studies evaluating different clinical
interventions used these scales to compare the patient
satisfaction between the intervention groups (60, 63, 74,
76, 79, 82, 83, 87, 8991)(9497). The only measure of
satisfaction that was comparable between studies was
‘willingness to return’, which was used in six studies (61,
63, 71, 72, 79, 83) ranging between 55.4 and 96.3% (61, 71).
Discussion
We have presented a systematic review on complications
and discomfort of FB. Severe complications were rare;
pneumothorax requiring intervention was reported in
02.1% of patients who had undergone TBB (64, 72).
Mortality rate was low, but it was difficult to compare
between studies that were performed on more or less
selected populations. The willingness to repeat broncho-
scopy was well above 50%.
Rates of specific complications ranged considerably, as
in the case of oxygen desaturation [0.776.3% of patients
(80, 81)] and bleeding (2.589.9% of patients) (59, 62).
There are several potential reasons for this: the wide range
of definitions (discussed below), different schemes for
data collection, differences in equipment and techniques,
differences between patient populations, and possibly
time-dependent inter-study differences, as there are more
than 40 years of gap between the publications included
in this review. We argue that the considerable variability
in complication rates can be attributed to a lack of con-
sensus on how to define and measure complications
and that many of the presented studies have a modest
sample size.
Patient tolerance was difficult to assess as all studies
utilised different measures of discomfort. VAS and NRS
were mostly used to compare subgroups receiving differ-
ent drug regimens, and it was unclear whether the results
of these studies were representative for clinical practice.
Furthermore, absolute scale values were rarely pre-
sented in result sections, as relative comparison between
subgroups was preferred.
The closest we got to a mortality rate that is repre-
sentative of routine clinical practice was in one of the
excluded studies. Facciolongo and co-workers reported a
mortality rate of 0.02% in a large prospective study in 19
centres conducting diagnostic and therapeutic broncho-
scopy. All deaths were somehow related to patients with a
scheduled bronchoscopic laser treatment. This report was
excluded from our main review because the authors did
not specify how patients were selected for inclusion, and
with regard to other complications they reported an un-
usual low number of incidents (1.08% of procedures) (24).
That we had to resolve to referring an excluded article
when discussing a major outcome such as mortality
illustrated one potential weakness of our approach  we
might have applied much rigorous exclusion criteria.
However, the informed reader needs to evaluate the
external validity of the included studies, and we considered
a comprehensive description of the sampling process
as imperative for this purpose. We have also chosen to
exclude more specific procedures such as bronchoscopy in
the ICU, endobronchial ultrasound (EBUS), and inter-
ventional ultrasound, which should be topics of separate,
future reviews.
Although bronchoscopy appeared to be a safe proce-
dure in terms of mortality, bleeding, and pneumothoraces,
it was difficult to conclude regarding the frequency of
other specific complications. The inter-study variation in
definitions of specific complications was considerable
if the outcomes were defined at all. In particular, this
could be exemplified by the variation in desaturation and
bleeding rates, as well as cough, health care utilisation,
and discomfort. The variation in definitions of ‘complica-
tions’ can have several reasons, but it is likely due to the
researchers’ and clinicians’ perception of what can be
considered significant complications, and which adverse
events are relevant for a specific patient group. Definitions
may also vary due to available tools for recording adverse
events. We also observed a lack of studies addressing
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complications and discomfort related to specific sampling
techniques, sedation, duration of the procedure, and
experience of the bronchoscopist. Similarly, there were
few articles that reported patient characteristics related to
safety and discomfort, such as indication for broncho-
scopy, comorbidities, age, and pre-procedural anxiety.
In the case of hypoxaemia, only two of the studies that
provided desaturation rates specified a pre-procedural
minimum resting/room air saturation of the participants
(90%) (77, 79). Few subtopics in our article present
predictors of complications, and we cannot, finally, con-
clude on predictors of complication. This is mainly due to
predictors not being presented in the reviewed articles,
which could result from insufficient statistical power.
Conclusion
To conclude, bronchoscopy is a safe procedure in terms
of complications such as mortality, pneumothorax, and
bleeding that necessitate intervention. However, we
should be able to inform patients in less broad strokes,
with details concerning risk of both complications and
what clinicians would characterise as discomforts. To
provide this information, we need a sufficiently powered,
prospective study on a well-described sample with clear
definitions of complications that at least include mortal-
ity, pneumothorax, desaturation, bleeding, hypotension,
arrhythmia, fever, and ‘willingness to return’. Character-
istics of participants and procedures should be related to
the outcomes in order to identify high-risk procedures. In
addition, all complications should be characterised in
terms of necessary intervention.
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